Recursion Pharmaceuticals, Inc. (RXRX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 6.47M | 35.54M | 5.17M | 19.1M | 14.74M | 4.51M | 26.08M | 14.4M | 13.49M | 10.62M | 10.1M | 11.02M |
| Revenue Growth % | -56.11% | 687.81% | -80.16% | 32.62% | 9.3% | -57.54% | 158.19% | 30.76% | 11.18% | -22.32% | -22.61% | 43.94% |
| Cost of Goods Sold | 12.49M | 26.88M | 29.59M | 20.16M | 21.83M | 12.79M | 12.08M | 9.2M | 11.17M | 9.88M | 10.88M | 9.38M |
| COGS % of Revenue | 192.99% | 75.63% | 571.85% | 105.54% | 148.04% | 283.62% | 46.31% | 63.86% | 82.77% | 93.01% | 107.67% | 85.17% |
| Gross Profit | -6.02M | 8.66M | -24.42M | -1.06M | -7.08M | -8.28M | 14M | 5.21M | 2.33M | 743K | -775K | 1.63M |
| Gross Margin % | -92.99% | 24.37% | -471.85% | -5.54% | -48.04% | -183.62% | 53.69% | 36.14% | 17.23% | 6.99% | -7.67% | 14.83% |
| Gross Profit Growth % | 15.05% | 204.58% | -274.38% | -120.33% | -404.69% | -1214.8% | 1906.84% | 218.54% | 840.45% | -73.8% | 67.11% | 124.86% |
| Operating Expenses | 122.49M | 117M | 147.78M | 175.17M | 184.28M | 175.49M | 112.36M | 105.75M | 98.67M | 99.67M | 98.78M | 83.35M |
| OpEx % of Revenue | 1892.57% | 329.21% | 2855.73% | 916.97% | 1249.81% | 3890.16% | 430.78% | 734.16% | 731.34% | 938.19% | 977.78% | 756.62% |
| Selling, General & Admin | 34.59M | 33.66M | 41.63M | 46.65M | 54.65M | 77.19M | 37.76M | 31.83M | 31.41M | 30.46M | 29.2M | 28.29M |
| SG&A % of Revenue | 534.47% | 94.71% | 804.41% | 244.22% | 370.63% | 1711.06% | 144.76% | 221% | 232.81% | 286.69% | 289.04% | 256.81% |
| Research & Development | 87.9M | 83.34M | 121.06M | 128.64M | 129.63M | 98.33M | 74.6M | 73.93M | 67.56M | 69.48M | 70.01M | 55.06M |
| R&D % of Revenue | 1358.1% | 234.51% | 2339.36% | 673.38% | 879.17% | 2179.87% | 286.02% | 513.25% | 500.78% | 654.01% | 693% | 499.82% |
| Other Operating Expenses | 0 | 0 | -1000K | -120K | 0 | -35K | 0 | -13K | -303K | -267K | -431K | -1K |
| Operating Income | -128.5M | -108.33M | -172.2M | -176.23M | -191.37M | -183.77M | -98.35M | -100.54M | -96.34M | -98.93M | -99.55M | -81.72M |
| Operating Margin % | -1985.55% | -304.84% | -3327.57% | -922.51% | -1297.85% | -4073.78% | -377.1% | -698.02% | -714.11% | -931.19% | -985.45% | -741.78% |
| Operating Income Growth % | 32.85% | 41.05% | -75.08% | -75.28% | -98.64% | -85.76% | 1.2% | -23.04% | -37.89% | -62.23% | -59.09% | -23.45% |
| EBITDA | -108.83M | -88.86M | -151.16M | -152.38M | -172.04M | -170.82M | -91.16M | -91.58M | -88.96M | -91.38M | -91.97M | -76.17M |
| EBITDA Margin % | -1681.58% | -250.03% | -2920.95% | -797.67% | -1166.75% | -3786.68% | -349.5% | -635.76% | -659.42% | -860.1% | -910.43% | -691.47% |
| EBITDA Growth % | 36.74% | 47.98% | -65.82% | -66.4% | -93.38% | -86.94% | 0.89% | -20.22% | -34.51% | -58.18% | -54.36% | -20.14% |
| D&A (Non-Cash Add-back) | 19.67M | 19.48M | 21.04M | 23.85M | 19.33M | 12.95M | 7.2M | 8.97M | 7.38M | 7.55M | 7.58M | 5.54M |
| EBIT | -128.5M | -108.1M | -162.25M | -171.42M | -202.14M | -178.29M | -95.12M | -97.67M | -92.13M | -97.03M | -92.99M | -76.7M |
| Net Interest Income | 5.61M | 6.25M | 4.71M | 4.96M | 5.05M | 4.01M | 3.27M | 2.87M | 4.03M | 4.5M | 4.95M | 4.93M |
| Interest Income | 5.96M | 6.25M | 5.54M | 5.44M | 5.05M | 4.62M | 3.83M | 3.27M | 4.05M | 4.52M | 4.98M | 4.96M |
| Interest Expense | 350K | 0 | 833K | 480K | 0 | 605K | 553K | 394K | 20K | 26K | 25K | 26K |
| Other Income/Expense | 6.4M | 232K | 9.95M | 4.33M | -11.28M | 4.87M | 2.68M | 2.48M | 4.19M | 1.87M | 6.53M | 4.99M |
| Pretax Income | -122.11M | -108.1M | -162.25M | -171.9M | -202.65M | -178.9M | -95.67M | -98.06M | -92.15M | -97.06M | -93.02M | -76.73M |
| Pretax Margin % | -1886.71% | -304.19% | -3135.27% | -899.84% | -1374.33% | -3965.84% | -366.82% | -680.8% | -683.06% | -913.57% | -920.78% | -696.51% |
| Income Tax | -4.6M | 20K | 3K | 0 | -158K | 7K | 167K | -523K | -779K | -4.06M | 0 | 0 |
| Effective Tax Rate % | 3.77% | -0.02% | -0% | 0% | 0.08% | -0% | -0.17% | 0.53% | 0.85% | 4.19% | 0% | 0% |
| Net Income | -117.5M | -108.12M | -162.25M | -171.9M | -202.49M | -178.91M | -95.67M | -97.54M | -91.37M | -93M | -93.02M | -76.73M |
| Net Margin % | -1815.57% | -304.25% | -3135.32% | -899.84% | -1373.26% | -3965.99% | -366.82% | -677.17% | -677.29% | -875.34% | -920.78% | -696.5% |
| Net Income Growth % | 41.97% | 39.56% | -69.59% | -76.23% | -121.6% | -92.38% | -2.86% | -27.13% | -39.87% | -61.75% | -53.89% | -17.03% |
| Net Income (Continuing) | -117.5M | -108.12M | -162.25M | -171.9M | -202.49M | -178.91M | -95.84M | -97.54M | -91.37M | -93M | -93.02M | -76.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 |
| EPS Growth % | 56% | 60.38% | -5.88% | -2.5% | -28.21% | -32.5% | 20.93% | -5.26% | -21.88% | -29.03% | -26.47% | 0% |
| EPS (Basic) | -0.22 | -0.21 | -0.36 | -0.41 | -0.50 | -0.53 | -0.34 | -0.40 | -0.39 | -0.40 | -0.43 | -0.38 |
| Diluted Shares Outstanding | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M |
| Basic Shares Outstanding | 529.3M | 526.72M | 446.99M | 417.36M | 402.77M | 336.04M | 282.58M | 242.2M | 236.02M | 233.16M | 214.33M | 201.42M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - |